Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 20;140(20):2127–2141. doi: 10.1182/blood.2022016040

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Figure 4. — Increased MCL1 expression driven by NF-κB at VEN relapse. (A) Bar plots showing pathway enrichment analysis in clusters from Group III (predominantly cells from VEN-relapsed samples) vs clusters in Group I (predominantly cells from screening samples). (B) Violin plots showing NF-κB pathway gene enrichment in Group III relapsed clusters. (C) Relative expression of REL, RELB, and NFKB2 in screening (n = 7; on left) or relapse (n = 13) samples; 1 patient (CLL26; on right) progressed while off VEN. (D) Pearson correlation coefficients were calculated between MCL1 and all other genes. The r score between MCL1 and REL, RELB, or NFKB2 are indicated with red ticks at the bottom. (E) Heatmap showing the correlation in expression between the indicated genes in the relapsed samples. Red shades indicate stronger positive correlations. (F) UMAP projections (left) of CLL cells from CLL7 at relapse, with violin plots (right panels) showing inferred CN variation of 1q21 (MCL1) or relative expression of indicated prosurvival genes across the individual clusters. (G-H) c-REL ChIP and chromatin accessibility at the BCL2A1 (G) and MCL1 (H) loci 5000 kb upstream of the transcriptional start site (TSS) or 5000 kb downstream of the transcriptional end site (TES) in purified CLL cells from screening (blue) or relapsed (red) samples from CLL7.